Prasanta Purohit

Prasanta Purohit

Auto-generated profile, based on publicly available information

Prasanta Purohit

Multi-Disciplinary Research Unit (MRU), M.K.C.G. Medical College, Berhampur, India

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2012 in Hemoglobin
Verified
Journal Article
Closed access
DPDilip K. Patel
Dilip K. Patel
RMRanjeet S. Mashon
Ranjeet S. Mashon
SPSiris Patel
Siris Patel
BDBhabani S. Das
Bhabani S. Das
PPPrasanta Purohit
Prasanta Purohit
SBSubasa C. Bishwal
Subasa C. Bishwal
There are several questions pertaining to dosage, duration and potential long-term toxicity of hydroxyurea (HU) therapy. Use of HU is extremely limited in eastern India because of its high cost and apprehension of its toxicities. We undertook this study to assess the clinical, biochemical and hematological efficacy of minimal dose HU (10 mg/kg/day) in 118 sickle cell anemia patients (27 pediatric and 91 adults). The frequency of painful crises reduced significantly in 71.5 and 92.2% in pediatric and adult cases, respectively. Ninety-five percent of the patients became transfusion independent. The baseline Hb F, total hemoglobin (Hb), MCV, MCH and MCHC levels increased significantly, whereas the WBC, platelet count and total serum bilirubin values decreased significantly. This is the first study of minimal dose HU therapy in eastern India that showed impressive improvement in clinical and hematological parameters with minimal toxicity.

24 February 2014 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
SPSiris Patel
Siris Patel
PPPrasanta Purohit
Prasanta Purohit
RMRanjeet Singh Mashon
Ranjeet Singh Mashon
SDSnehadhini Dehury
Snehadhini Dehury
SMSatyabrata Meher
Satyabrata Meher
DPDilip Kumar Patel
Dilip Kumar Patel

11 March 2014 in ISRN Hematology
Verified
Journal Article
Open access
PDF file
PPPrasanta Purohit
Prasanta Purohit
SDSnehadhini Dehury
Snehadhini Dehury
SPSiris Patel
Siris Patel
DPDilip Kumar Patel
Dilip Kumar Patel
Inherited hemoglobin disorders like alpha thalassemia and sickle gene are common in the Indian subcontinent. These disorders in the heterozygous state act as malaria resistance genes and influence the susceptibility toPlasmodium falciparummalaria. There is inadequate knowledge about the epidemiology of these malaria resistance genes in the tribal dominated malaria endemic region of the state of Odisha in eastern India. A cross sectional prevalence study was undertaken in 594 subjects in five tribal populations in this region, namely, Sahara (42.4%), Kutia Kandha (30.0%), Kuda (15.8%), Gond (9.8%), and Oraon (2.0%). Sickling test, Hb electrophoresis, HPLC, and molecular studies were undertaken to diagnose the prevalence of sickle allele,β-thalassemia allele, and deletional alpha thalassemia. Sickle andβthalassemia alleles were found in 13.1% and 3.4% of subjects, respectively. Sickle allele was found both in heterozygous (10.1%) and homozygous state (3.03%). The prevalence of alpha thalassemia was 50.84% with an allelic frequency of 0.37. Bothα−3.7andα−4.2alpha thalassemia were detected with an allele frequency of 0.33 and 0.04, respectively. The high prevalence of alpha thalassemia and sickle gene in this population is probably due to selection pressure of endemic malaria in this part of India.

24 December 2014 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
SDSnehadhini Dehury
Snehadhini Dehury
PPPrasanta Purohit
Prasanta Purohit
SPSiris Patel
Siris Patel
SMSatyabrata Meher
Satyabrata Meher
BKBipin Kishore Kullu
Bipin Kishore Kullu
DPDilip Kumar Patel
Dilip Kumar Patel

19 November 2013 in International Journal of Laboratory Hematology
Verified
Journal Article
Closed access
PDF file
DPD. K. Patel
D. K. Patel
PPP. Purohit
P. Purohit
SDS. Dehury
S. Dehury
PDP. Das
P. Das
ADAmbarish Dutta
Ambarish Dutta
KDK. Das
K. Das

1 May 2018 in Journal of Infection and Public Health
Verified
Journal Article
Open access
PPPrasanta Purohit
Prasanta Purohit
PMPradeep K. Mohanty
Pradeep K. Mohanty
SPSiris Patel
Siris Patel
PDPadmalaya Das
Padmalaya Das
JPJogeswar Panigrahi
Jogeswar Panigrahi
KDKishalaya Das
Kishalaya Das
Sickle-cell-gene has a high frequency in malaria endemic regions. In India, though the prevalence of both sickle-cell-gene and malaria are high, no study has been carried out. This study aims to find out the possible differences in hematological and clinical parameters in severe falciparum malaria with respect to sickle cell genotypes. Five hundred fourteen adults with severe falciparum malaria hospitalized in Department of Medicine, Veer Surendra Sai Institute of Medical Sciences and Research, Burla, between August, 2010 to December, 2014 were included and categorized on the basis of sickle cell genotypes. The hematological parameters were compared by one-way-analysis-of-variance and incidence of sub-phenotypes of severe malaria was compared by χ2 test across the groups. Patients with sickle cell anemia (HbSS) and severe falciparum malaria had lower hemoglobin level compared to patients with normal β-globin genotype (HbAA) and sickle cell trait (HbAS). Most of the hematological parameters were homogeneous in patients with HbAA and HbAS and different from patients with HbSS. Incidence of acute renal failure was low (χ2, 9.91; p, 0.002) and jaundice was high (χ2, 5.20; p, 0.022) in patients with HbSS. No clinical difference was observed in patients with HbAA and HbAS. The mortality was low (χ2, 4.33; p, 0.037) and high (χ2, 10.48; p, 0.001) in patients with HbAS and HbSS respectively compared to patients with HbAA. Though sickle-cell-gene protects against falciparum infections, the hematological parameters and sub-phenotypes of severe malaria remain unchanged when the infection progresses to a severe form in patients with HbAA and HbAS. Presence of hemolytic anemia in patients with HbSS shows diverse hematological and clinical phenotypes as compared to others. High mortality in patients with HbSS emphasizes the need for a better preventive approach to save valuable lives.